United States · Business news · Corporate · 06 Oct 2026
US Health Care
Private equity firm Clayton, Dubilier & Rice and drug distributor McKesson signed an agreement to acquire Option Care Health for $32.05 a share in cash, an enterprise value of about $5.8 billion and roughly 37% above the October 5 closing price. CD&R takes about 51% and McKesson about 49% for an investment of about $1.4 billion; the agreement sets terms under which McKesson can later buy CD&R's interest. Five banks have committed financing. Closing is planned for the first half of 2027, subject to a shareholder vote and regulatory clearances.
Option Care gives infusion drugs at home and in clinics instead of hospitals, a channel insurers favour because it costs less. McKesson, which already distributes specialty drugs, gains a stake in the provider that administers them, and a path to full ownership. For other US drug distributors and home-health companies the deal sets a reference price — a 37% premium — and continues the move of distributors into care delivery. Hospital outpatient infusion departments are the business on the other side of that shift.
Reported by McKesson (SEC filing) — “CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health” ↗ on 06 Oct 2026.
Official series on 06 Oct 2026 or the last day before it, and the latest observation.
The advance was narrow: the report notes only about 25% of S&P 500 companies were trading above their 50-day average, and smaller companies fell on the day. Index gains are coming from AI chipmakers and from power…
Epcoritamab, sold as EPKINLY in the US and Japan and TEPKINLY in the EU, is approved so far for lymphoma that has returned after earlier treatment. A first-line label would open a much larger group of patients, and…
These are the first US deals to launch in the fourth quarter, and both are small, clinical-stage companies with no product revenue: the money funds trials. TRex Bio's lead programme has topline data due in mid-2027 and…
An empty week means no underwriting fees for the banks that run US listings and no new supply for funds that buy them. Renaissance's IPO Index was up 16.4% for the year at October 1 against 13.0% for the S&P 500, so…